News By Tag * Rheumatoid * Arthritis * Drug * Actemra * Receiving * Clinical * Trial * Therapy * Orencia * Patient * More Tags... Industry News News By Location Country(s) Industry News
|  Product Profiles: Disease Modification in Rheumatoid ArthritisNew Pharmaceuticals market report from Datamonitor: "Product Profiles: Disease Modification in Rheumatoid Arthritis - Game-changing therapy close to market"
By: Fast Market Research, Inc. Report Scope: * Access Datamonitor's independent appraisal of prominent brands and pipeline agents for rheumatoid arthritis. * Enhance understanding of how marketed and pipeline drugs compare to one another in terms of clinical and commercial attributes. * Review important clinical developments of novel late-stage pipeline candidates, with analysis of new clinical trial data. * Gain insight into physician perception and product positioning in the treatment algorithm of key brands. ------------------------------------------------------------ Full Report Details at - http://www.fastmr.com/ ------------------------------------------------------------ Report Highlights With a novel mode of action, efficacy in line with biologics, and positive data from an active comparator trial versus first-line contender Humira (adalimumab; Bristol-Myers Squibb executed a key lifecycle management strategy of intravenous brand Orencia with the US launch of a subcutaneous (SC) form in 2011. Enhancing its treatment offering relative to Roche's Rituxan (rituximab; Biogen Idec) and Actemra (tocilizumab) Roche's attempt to change market dynamics with Actemra continues. With two ongoing head-to-head trials versus Humira, it has also filed with the FDA to revise Actemra's label. If granted, it could mean an unprecedented shift in RA treatment, as Actemra, a non-TNF biologic, could be selected ahead of dominant TNF inhibitors Enbrel and Humira. Reasons to Get this Report: * What are the comparative strengths, weaknesses, opportunities, and threats of the key rheumatoid arthritis products and pipeline candidates? * To what extent do future therapies satisfy the main clinical unmet needs in rheumatoid arthritis treatment? * How do rheumatologists perceive key marketed and pipeline agents relative to clinical and commercial attributes? * What strategies are rheumatoid arthritis market players carrying out in the face of intensifying competition? Partial Table of Contents: OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports PRODUCT OVERVIEW Key marketed and pipeline products MARKETED PRODUCT PROFILES Enbrel (etanercept; Drug profile Development overview SWOT analysis Product positioning Use by line of therapy Physician perception of Enbrel Clinical and commercial attractiveness Humira (adalimumab; Drug profile Development overview SWOT analysis Product positioning Clinical and commercial attractiveness Remicade (infliximab; Drug profile Development overview SWOT analysis Product positioning Clinical and commercial attractiveness Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) Drug profile Development overview SWOT analysis Product positioning Physician perception of Simponi Clinical and commercial attractiveness Cimzia (certolizumab; Drug profile Development overview SWOT analysis Product positioning Physician perception of Cimzia Clinical and commercial attractiveness Actemra/RoActemra (tocilizumab; Drug profile Development overview SWOT analysis Product positioning Up to 64% of all patients receiving intravenous Actemra would be switched to subcutaneous formulation Physician perception of Actemra Clinical and commercial attractiveness Orencia (abatacept; Bristol-Myers Squibb) Drug profile Development overview SWOT analysis Product positioning Physician perception of Orencia Clinical and commercial attractiveness Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/Chugai) Drug profile Development overview SWOT analysis Product positioning Physician perception of Rituxan/MabThera Clinical and commercial attractiveness PIPELINE PRODUCT PROFILES Tofacitinib (formerly tasocitinib, CP-690,550; Pfizer) Drug profile Development overview SWOT analysis Satisfaction of unmet needs Physician perception of tofacitinib Clinical and commercial attractiveness FosD (fostamatinib disodium, R788; AstraZeneca/ Drug profile Development overview SWOT analysis Satisfaction of unmet needs Clinical and commercial attractiveness Other drugs in development for rheumatoid arthritis AIN457 (secukinumab; Development overview SWOT analysis Satisfaction of unmet needs BIBLIOGRAPHY Journal papers Websites Datamonitor reports APPENDIX A - SURVEY INFORMATION Datamonitor's rheumatoid arthritis survey Physician sample breakdown Primary research questions APPENDIX B Datamonitor drug assessment scorecard Contributing experts Conferences attended Report methodology TABLES Table: Key marketed and pipeline products for rheumatoid arthritis, 2012 Table: Enbrel (etanercept; Table: Overview of pivotal trial data for Enbrel in rheumatoid arthritis, 2012 Full Table of Contents is available at: -- http://www.fastmr.com/ About Datamonitor The Datamonitor Group is a world-leading provider of premium global business information, delivering independent data, analysis and opinion across the Automotive, Consumer Markets, Energy & Utilities, Financial Services, Logistics & Express, Pharmaceutical & Healthcare, Retail, Technology and Telecoms industries. Datamonitor's market intelligence products and services ensure that you will achieve your desired commercial goals by giving you the insight you need to best respond to your competitive environment. View more research from Datamonitor at http://www.fastmr.com/ # # # Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available. End
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number